Grant: Alliance Grants
Université de Montréal
$25,000.00
Advancing in vitro to in vivo extrapolation tools for new generation risk assessment
FY 2024-25
Summary
Risk assessment has traditionally relied on animal experiments to evaluate whether chemicals are toxic, and to determine doses in humans at which no adverse effect is expected. Because animal tests are time- and resource-intensive, and because of the questionable predictability of animal toxicity data in the context of human health risk assessment, there is currently a global shift away from animal testing to embrace faster, cheaper, and human-relevant alternative approaches to tackle the tens of thousands of chemicals on the market. The recent amendments to the Canadian Environment Protection Act confirm Canada's desire to contribute to this transition. However, there are still hurdles to the adoption of new approaches for risk assessment, namely in terms of validation. Some studies have evaluated whether in vitro tests coupled with computational modeling could be used to replace animal testing, but results have been mostly compared to animal test results. In line with the recent recommendations by the National Academies of Sciences, Engineering and Medicine, my team recently started to evaluate new approach methodologies (also known as NAMs) by comparing tolerable daily intakes derived from in vitro studies to exposure data from epidemiological studies reporting associations with adverse health outcomes. The long-term objective is to generate a series of case studies to build confidence and identify limitations of new approach methods for risk assessors and policy-makers. In this Catalyst project, we aim to strengthen our team by collaborating with Nynke Kramer (Wageningen University & Research, Netherlands) and Fabian Fischer (University of Rhode Island, USA), two internationally recognized experts in in vitro toxicology and modeling of chemical distribution in in vitro systems. Through this collaboration, we will advance tools for in vitro to in vivo extrapolation, which will contribute to the transition away from animal testing.
Program
Alliance Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
597461-2024
Name nom
Verner, Marc-André M-A
Department département
Santé environnementale et santé au travail
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
25000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
406
Area of application group en
Environment
Area of application group fr
Environnement
Area of application en
Pollutants and toxic agents (waste, use 902)
Area of application fr
Polluants et agents toxiques (déchets, utiliser 902)
Research subject code
6403
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Toxicology
Research subject fr
Toxicologie
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Advancing in vitro to in vivo extrapolation tools for new generation risk assessment
Keywords
dose-response modeling; environmental epidemiology; human equivalent dose; in vitro assays; in vitro-in vivo extrapolation; mass-balance modeling; neurotoxicology; pharmacokinetic modeling; risk assessment
Application summary
Risk assessment has traditionally relied on animal experiments to evaluate whether chemicals are toxic, and to determine doses in humans at which no adverse effect is expected. Because animal tests are time- and resource-intensive, and because of the questionable predictability of animal toxicity data in the context of human health risk assessment, there is currently a global shift away from animal testing to embrace faster, cheaper, and human-relevant alternative approaches to tackle the tens of thousands of chemicals on the market. The recent amendments to the Canadian Environment Protection Act confirm Canada's desire to contribute to this transition. However, there are still hurdles to the adoption of new approaches for risk assessment, namely in terms of validation. Some studies have evaluated whether in vitro tests coupled with computational modeling could be used to replace animal testing, but results have been mostly compared to animal test results. In line with the recent recommendations by the National Academies of Sciences, Engineering and Medicine, my team recently started to evaluate new approach methodologies (also known as NAMs) by comparing tolerable daily intakes derived from in vitro studies to exposure data from epidemiological studies reporting associations with adverse health outcomes. The long-term objective is to generate a series of case studies to build confidence and identify limitations of new approach methods for risk assessors and policy-makers. In this Catalyst project, we aim to strengthen our team by collaborating with Nynke Kramer (Wageningen University & Research, Netherlands) and Fabian Fischer (University of Rhode Island, USA), two internationally recognized experts in in vitro toxicology and modeling of chemical distribution in in vitro systems. Through this collaboration, we will advance tools for in vitro to in vivo extrapolation, which will contribute to the transition away from animal testing.